AU2014349246C1 - Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases - Google Patents

Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases Download PDF

Info

Publication number
AU2014349246C1
AU2014349246C1 AU2014349246A AU2014349246A AU2014349246C1 AU 2014349246 C1 AU2014349246 C1 AU 2014349246C1 AU 2014349246 A AU2014349246 A AU 2014349246A AU 2014349246 A AU2014349246 A AU 2014349246A AU 2014349246 C1 AU2014349246 C1 AU 2014349246C1
Authority
AU
Australia
Prior art keywords
eosinophilic
diseases
compound
atopic dermatitis
bronchial asthma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014349246A
Other languages
English (en)
Other versions
AU2014349246B2 (en
AU2014349246A1 (en
AU2014349246A9 (en
Inventor
Alexander Grigorievich Chuchalin
Tatyana Alexandrovna Kromova
Vladimir Evgenievich Nebolsin
Anastasia Vladimirovna RYDLOVSKAYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemimmune Therapeutics LLC
Original Assignee
Chemimmune Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemimmune Therapeutics LLC filed Critical Chemimmune Therapeutics LLC
Publication of AU2014349246A1 publication Critical patent/AU2014349246A1/en
Publication of AU2014349246A9 publication Critical patent/AU2014349246A9/en
Publication of AU2014349246B2 publication Critical patent/AU2014349246B2/en
Priority to AU2018264084A priority Critical patent/AU2018264084C1/en
Application granted granted Critical
Publication of AU2014349246C1 publication Critical patent/AU2014349246C1/en
Assigned to “ChemImmune Therapeutics” Limited Liability Company reassignment “ChemImmune Therapeutics” Limited Liability Company Request for Assignment Assignors: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES"
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2014349246A 2013-11-14 2014-11-12 Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases Ceased AU2014349246C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018264084A AU2018264084C1 (en) 2013-11-14 2018-11-15 Pharmaceutical composition comprising glutarimide derivatives, and application thereof for treating eosinophilic diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
RU2013150861 2013-11-14
PCT/RU2014/000855 WO2015072893A1 (ru) 2013-11-14 2014-11-12 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018264084A Division AU2018264084C1 (en) 2013-11-14 2018-11-15 Pharmaceutical composition comprising glutarimide derivatives, and application thereof for treating eosinophilic diseases

Publications (4)

Publication Number Publication Date
AU2014349246A1 AU2014349246A1 (en) 2016-05-19
AU2014349246A9 AU2014349246A9 (en) 2018-09-20
AU2014349246B2 AU2014349246B2 (en) 2018-10-18
AU2014349246C1 true AU2014349246C1 (en) 2019-02-21

Family

ID=53057723

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014349246A Ceased AU2014349246C1 (en) 2013-11-14 2014-11-12 Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
AU2018264084A Ceased AU2018264084C1 (en) 2013-11-14 2018-11-15 Pharmaceutical composition comprising glutarimide derivatives, and application thereof for treating eosinophilic diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018264084A Ceased AU2018264084C1 (en) 2013-11-14 2018-11-15 Pharmaceutical composition comprising glutarimide derivatives, and application thereof for treating eosinophilic diseases

Country Status (23)

Country Link
US (2) US9949962B2 (enExample)
EP (2) EP3466425B1 (enExample)
JP (4) JP2016540749A (enExample)
KR (2) KR102312013B1 (enExample)
CN (2) CN110200968A (enExample)
AU (2) AU2014349246C1 (enExample)
BR (1) BR112016010515B1 (enExample)
CA (1) CA2930231C (enExample)
CY (1) CY1122500T1 (enExample)
DK (1) DK3069720T3 (enExample)
EA (4) EA032940B1 (enExample)
ES (2) ES2836887T3 (enExample)
HU (1) HUE046671T2 (enExample)
IL (2) IL245429B (enExample)
LT (1) LT3069720T (enExample)
MX (2) MX386887B (enExample)
PL (2) PL3069720T3 (enExample)
PT (1) PT3069720T (enExample)
RU (1) RU2552929C1 (enExample)
SG (1) SG10201900504XA (enExample)
SI (1) SI3069720T1 (enExample)
UA (1) UA118687C2 (enExample)
WO (1) WO2015072893A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MX380619B (es) * 2013-04-12 2025-03-12 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US10370449B2 (en) 2014-02-28 2019-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
CN111093661B (zh) * 2017-09-07 2023-10-27 化学免疫疗法有限责任公司 戊二酰亚胺衍生物用于治疗与细胞因子的异常活性相关的疾病的用途
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
CN113597328B (zh) 2019-03-21 2025-10-31 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
SG11202113310UA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
EP4010001A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
WO2021207367A1 (en) * 2020-04-07 2021-10-14 Hofseth Biocare Asa Respiratory treatments using salmonid oil compositions
CN115803026A (zh) * 2020-06-26 2023-03-14 瓦伦塔有限责任公司 戊二酰亚胺衍生物用于治疗与异常白介素-6活性相关的疾病的用途
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024133A1 (en) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196767A (ja) 1988-10-11 1990-08-03 Kyowa Hakko Kogyo Co Ltd ヒドロキサム酸誘導体
AU9134191A (en) 1990-12-24 1992-07-22 Merrell Dow Pharmaceuticals Inc. Use of certain glutarimide derivatives in the treatment of depression and mania
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
CA2466492A1 (en) 2001-11-07 2003-05-15 Cytos Biotechnology Ag Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
CN101848732B (zh) 2007-05-14 2013-06-05 米迪缪尼有限公司 降低嗜酸性粒细胞水平的方法
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств
MX380619B (es) 2013-04-12 2025-03-12 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024133A1 (en) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors

Also Published As

Publication number Publication date
CA2930231C (en) 2022-06-14
MX2016006330A (es) 2016-09-06
IL271352A (en) 2020-01-30
JP2019214606A (ja) 2019-12-19
IL245429A0 (en) 2016-06-30
CY1122500T1 (el) 2021-01-27
US10220029B2 (en) 2019-03-05
KR20200053639A (ko) 2020-05-18
EP3466425A1 (en) 2019-04-10
US20180104230A1 (en) 2018-04-19
EA201990529A1 (ru) 2019-07-31
BR112016010515B1 (pt) 2022-09-27
US20160279114A1 (en) 2016-09-29
EP3466425B1 (en) 2020-10-07
DK3069720T3 (da) 2019-11-25
IL245429B (en) 2020-02-27
AU2014349246B2 (en) 2018-10-18
EP3069720A1 (en) 2016-09-21
SG10201900504XA (en) 2019-02-27
PL3069720T3 (pl) 2020-05-18
EP3069720A8 (en) 2017-10-04
KR20160078400A (ko) 2016-07-04
CN105722511A (zh) 2016-06-29
LT3069720T (lt) 2020-01-10
EA201891262A1 (ru) 2018-10-31
JP2019055953A (ja) 2019-04-11
MX2019006881A (es) 2019-08-01
RU2552929C1 (ru) 2015-06-10
KR102312013B1 (ko) 2021-10-15
AU2018264084A1 (en) 2018-12-06
RU2013150861A (ru) 2015-05-20
EA032955B1 (ru) 2019-08-30
CN105722511B (zh) 2019-09-17
EA030961B1 (ru) 2018-10-31
JP6589251B2 (ja) 2019-10-16
JP6758677B2 (ja) 2020-09-23
EP3069720A4 (en) 2017-06-21
AU2018264084C1 (en) 2020-08-27
CA2930231A1 (en) 2015-05-21
JP2016540749A (ja) 2016-12-28
EA201690798A1 (ru) 2016-08-31
CN110200968A (zh) 2019-09-06
BR112016010515A2 (enExample) 2017-08-08
UA118687C2 (uk) 2019-02-25
AU2014349246A1 (en) 2016-05-19
PT3069720T (pt) 2019-12-02
EA037447B1 (ru) 2021-03-30
ES2836887T3 (es) 2021-06-28
EA032955B3 (ru) 2020-02-27
AU2018264084B2 (en) 2020-05-14
AU2014349246A9 (en) 2018-09-20
ES2759530T3 (es) 2020-05-11
KR102312294B1 (ko) 2021-10-15
SI3069720T1 (sl) 2020-02-28
WO2015072893A1 (ru) 2015-05-21
MX386887B (es) 2025-03-19
EA032940B1 (ru) 2019-08-30
EP3069720B1 (en) 2019-10-30
MX365781B (es) 2019-06-13
JP2020002152A (ja) 2020-01-09
PL3466425T3 (pl) 2021-04-06
US9949962B2 (en) 2018-04-24
EA201891261A1 (ru) 2018-10-31
HUE046671T2 (hu) 2020-03-30
IL271352B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
AU2014349246C1 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
WO2017167182A1 (zh) 一种选择性的c-kit激酶抑制剂
KR102418211B1 (ko) 일시적 수용체 전위 a1 이온 채널의 억제
HK40007097B (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
HK40007097A (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
HK1224930B (zh) 包含戊二酰亚胺衍生物的药物组合物及其用於治疗嗜酸细胞性疾病的用途
WO2020087565A1 (zh) 吲唑类激酶抑制剂及其用途
HK1224930A1 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
KR20250131623A (ko) 히스톤 탈아세틸효소 저해제를 포함하는 다중 글루타민 질병의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
SREP Specification republished
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 NOV 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 09 NOV 2018

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CHEMIMMUNE THERAPEUTICS LIMITED LIABILITY COMPAN

Free format text: FORMER OWNER(S): OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES"

MK14 Patent ceased section 143(a) (annual fees not paid) or expired